| Minh Tran Luong, MD | |
|
5602 E Main St, Mesa, AZ 85205-8813 | |
| (480) 854-9004 | |
| (480) 854-8543 |
| Full Name | Minh Tran Luong |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 21 Years |
| Location | 5602 E Main St, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083820781 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 41809 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Gilbert Medical Center | Gilbert, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arizona Family And Geriatric Medicine, Pllc | 3476733551 | 2 |
| Bhsm Rehabilitation Llc | 2062773138 | 1258 |
News Archive
World Health Organization Director-General Margaret Chan in a letter to Thai Health Minister Mongkol na Songkhla said that although the Thai government was fully within its rights to issue a compulsory license for Abbott Laboratories antiretroviral drug Kaletra, countries should find the "right balance" between providing affordable medicines and incentives for drug companies to develop new treatments.
To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.
Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.
New findings reported in the July issue of Cell Metabolism, a Cell Press publication, are offering new leads as to why some people might suffer from high levels of triglycerides. High triglycerides are a risk factor for atherosclerosis and cardiovascular disease. They can also lead to inflammation of the pancreas, the researchers said.
Loyola University Medical Center pediatrician Dr. Kathleen Webster, a leader in the growing field of telemedicine, is being honored by the American Telemedicine Association.
› Verified 6 days ago
| Entity Name | Arizona Family & Geriatric Medicine, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740596733 PECOS PAC ID: 3476733551 Enrollment ID: O20110207000497 |
News Archive
World Health Organization Director-General Margaret Chan in a letter to Thai Health Minister Mongkol na Songkhla said that although the Thai government was fully within its rights to issue a compulsory license for Abbott Laboratories antiretroviral drug Kaletra, countries should find the "right balance" between providing affordable medicines and incentives for drug companies to develop new treatments.
To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.
Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.
New findings reported in the July issue of Cell Metabolism, a Cell Press publication, are offering new leads as to why some people might suffer from high levels of triglycerides. High triglycerides are a risk factor for atherosclerosis and cardiovascular disease. They can also lead to inflammation of the pancreas, the researchers said.
Loyola University Medical Center pediatrician Dr. Kathleen Webster, a leader in the growing field of telemedicine, is being honored by the American Telemedicine Association.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Minh Tran Luong, MD 5602 E Main St, Mesa, AZ 85205-8813 Ph: (480) 854-9004 | Minh Tran Luong, MD 5602 E Main St, Mesa, AZ 85205-8813 Ph: (480) 854-9004 |
News Archive
World Health Organization Director-General Margaret Chan in a letter to Thai Health Minister Mongkol na Songkhla said that although the Thai government was fully within its rights to issue a compulsory license for Abbott Laboratories antiretroviral drug Kaletra, countries should find the "right balance" between providing affordable medicines and incentives for drug companies to develop new treatments.
To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.
Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.
New findings reported in the July issue of Cell Metabolism, a Cell Press publication, are offering new leads as to why some people might suffer from high levels of triglycerides. High triglycerides are a risk factor for atherosclerosis and cardiovascular disease. They can also lead to inflammation of the pancreas, the researchers said.
Loyola University Medical Center pediatrician Dr. Kathleen Webster, a leader in the growing field of telemedicine, is being honored by the American Telemedicine Association.
› Verified 6 days ago
Dr. Jose Rapanan Jr., DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10032 E Southern Ave, Mesa, AZ 85209 Phone: 480-351-2850 | |
Jennifer Christine Fendler, NP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 924 N Country Club Dr, Mesa, AZ 85201 Phone: 480-601-3528 | |
George Ting, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1111 N Stapley Dr, Mesa, AZ 85203 Phone: 480-464-8500 | |
Dr. Thomas P Porter, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1950 S Country Club Dr, Mesa, AZ 85210 Phone: 480-969-1446 Fax: 480-969-9105 | |
Dana S Farris, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10238 E Hampton Ave Ste 506, Mesa, AZ 85209 Phone: 480-834-7546 Fax: 480-833-8313 | |
Nancy Mucha, CNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2843 N 89th St, Mesa, AZ 85207 Phone: 480-396-3482 | |
Ryan Elisabeth Romo, Family Medicine Medicare: Medicare Enrolled Practice Location: 1705 W Main St, Mesa, AZ 85201 Phone: 877-809-5092 |